Alcon, the eye care business of Novartis, has opened an ophthalmic pharmaceutical manufacturing facility in the Tuas Biomedical Park in Singapore. Construction on the 330,000-square foot facility began in 2009 and represents an investment of approximately S$200 million (US$239 million). The plant produces ophthalmic pharmaceutical products that address eye conditions such as glaucoma, dry eye, allergies and bacterial infections. Currently, the facility employs approximately 150 associates, and is expected to continue to grow as production increases.
  
Alcon has more than 20 manufacturing facilities around the world. In 2005, the company opened a contact lens manufacturing facility in Singapore.

Source: Alcon